This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Life Technologies To Accelerate Adoption Of Next-Generation Sequencing In HLA Through Key Partnerships

CARLSBAD, Calif., April 4, 2012 /PRNewswire/ --  Life Technologies Corporation (NASDAQ: LIFE) today announced that it is working with several partners to develop applications for its Ion Personal Genome Machine (PGM™) system in HLA (human leukocyte antigen) analysis.

HLAs are found on the surfaces of all cells in the body, and individuals vary widely in the combination of HLA sub-types found in their tissues.  Tissue typing by HLA analysis is an essential component of determining organ and bone marrow transplant compatibility between donors and patients.  Accurate typing is needed to reduce the possibility of transplant rejection or the risk of graft versus host disease.  HLAs are coded by a group of genes referred to as the MHC (major histocompatibility complex).

Life Technologies intends to enter into a Sponsored Research Agreement with the Histocompatibility, Immunogenetics, and Disease Profiling Laboratory at the Stanford Department of Pathology.  The researchers include Dolly Tyan, Ph.D., Marcelo Fernandez-Vina, Ph.D., and Matthew Anderson, M.D., Ph.D., who in a joint statement indicated, "Next-generation sequencing technologies offer an exciting new approach to understanding the unmapped genetic variation of the MHC.  We believe the speed, throughput, and automated workflow of a system of this kind may help our efforts to better define this important genetic region for disease associations and clinical transplantation."

Howard Martin, Ph.D. of Addenbrookes Hospital - Cambridge has already begun working with the Ion PGM system and has deployed novel informatics strategies to obtain effective reads of the MHC using existing chemistries.  "The speed and flexibility of the Ion PGM system has enabled us to rapidly develop our HLA sequencing strategy. As read lengths improve, so too does quality and scalability," said Martin, who described his early work in a webinar in October 2011.

"Next generation sequencing offers significant potential to the HLA community. We are particularly interested in the Ion PGM system in light of its technological advantages, rapid throughput, and operational simplicity and we believe it offers an excellent path forward for our laboratory," said Paul Keown, M.D., DSc, Director of Immunology and Head of Nephrology, University of British Columbia.

The transplant diagnostics field represents a $400M global marketplace within the medical sciences.  "Life Technologies is committed to expanding in areas of medical sciences in which genomics can play a critical role in improving patient outcomes," said Ronnie Andrews, president of medical sciences at Life Technologies. "Life believes that the Ion Torrent disruptive technology, including increasing read length and throughput, make it a very promising tool for transplant research."

Life Technologies currently markets the 3500 Capillary Electrophoresis platform and SeCore® kits as a Research Use Only (RUO) product in the United States; these products are also CE-IVD approved in Europe. The Ion PGM system is currently for research purposes only and is not intended for diagnostic uses.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs